Takeda's dengue vaccine candidate provides continued protection against dengue fever through 4.5 years in pivotal clinical trial

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that its dengue vaccine candidate, tak-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population including both seropositive and seronegative individuals through four and a half years (54 months) after vaccination in the pivotal phase 3 tetravalent immunization against dengue efficacy study (tides) trial. the
TAK Ratings Summary
TAK Quant Ranking